Literature DB >> 10657903

Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers.

Y Yaginuma1, T Yamashita, T Ishiya, A Morizaki, Y Katoh, T Takahashi, H Hayashi, M Ishikawa.   

Abstract

The PTEN/MMAC1 gene, located on human chromosome 10q23, has recently been implicated as a candidate tumor suppressor gene in human cancers. In the present study, 12 uterine cancer cell lines and 87 uterine cancers of various grades and histological type were analyzed for PTEN/MMAC1 gene. Three of 44 endometrial carcinoma (7%) showed no PTEN/MMAC1 mRNA expression by RT-PCR analysis. Sequencing analysis of entire coding region of PTEN/MMAC1 gene revealed mutations in three of six endometrial cancer cell lines (50%) and 17 of 44 endometrial cancer tissues (39%). In contrast, for cervical cancers, only one of six cancer cell lines (2%) showed mutation, and one of 43 cancer tissues (2%) had an abnormality. Overall, 36% of the abnormal spots were located in exon 5, 24% were in exon 8, 16% were in exon 3, and 8% were in exon 6, and single cases of abnormality were found in exons 1, 4, and 7. Our results revealed that, in total, 60% of abnormalities were clustered in exons 5 and 8. Exon 5 is a functional domain of the PEN/MMAC1 gene, and therefore, abnormalities in this region may be important for loss of PTEN/MMAC1 gene function. Finally, we found a high frequency of PTEN/MMAC1 gene abnormalities in endometrial carcinomas but a low frequency in cervical carcinomas. These findings suggest that disruption of PTEN/MMAC1 by mutation or absence of expression may contribute to the pathogenesis or neoplastic evolution in a large proportion of endometrial carcinomas but in a small proportion of cervical carcinomas. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657903     DOI: 10.1002/(sici)1098-2744(200002)27:2<110::aid-mc6>3.0.co;2-e

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  11 in total

1.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

Authors:  Katherine L Nathanson; Anne-Marie Martin; Bradley Wubbenhorst; Joel Greshock; Richard Letrero; Kurt D'Andrea; Steven O'Day; Jeffrey R Infante; Gerald S Falchook; Hendrik-Tobias Arkenau; Michael Millward; Michael P Brown; Anna Pavlick; Michael A Davies; Bo Ma; Robert Gagnon; Martin Curtis; Peter F Lebowitz; Richard Kefford; Georgina V Long
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

3.  Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines.

Authors:  Lineng Zhang; Qiang Yu; Jianyu He; Xiliang Zha
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

4.  PTEN mutation spectrum in breast cancers and breast hyperplasia.

Authors:  Julun Yang; Yan Ren; Li Wang; Baolin Li; Yue Chen; Wenxing Zhao; Wenmang Xu; Tao Li; Fang Dai
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-19       Impact factor: 4.553

5.  Long-term effects of repeated superovulation on the uterus and mammary gland in rhesus monkeys.

Authors:  Peipei Yan; Jingyi Xu; Yan Zeng; Guoying Dong; Huarong Cao; Meimei Zheng; Hui Zhu
Journal:  J Assist Reprod Genet       Date:  2017-01-23       Impact factor: 3.412

6.  Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer.

Authors:  Qiufeng Qi; Yang Ling; Ming Zhu; Linyan Zhou; Meizhen Wan; Yanqing Bao; Yongping Liu
Journal:  Biomed Rep       Date:  2014-06-16

7.  Effects of indomethacin on expression of PTEN tumour suppressor in human cancers.

Authors:  Imran Haruna Abdulkareem; Maria Blair
Journal:  Niger Med J       Date:  2013-03

8.  Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab.

Authors:  Debora D Meira; Vitor H Almeida; Jânio S Mororó; Mauricio S Caetano; Isabel P Nóbrega; Delano Batista; Cinthya Sternberg; Carlos G Ferreira
Journal:  Mol Cancer       Date:  2011-12-20       Impact factor: 27.401

9.  Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.

Authors:  M H Kulke; R D Odze; K S Thakore; G Thomas; H Wang; M Loda; C Eng
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

10.  Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells.

Authors:  X Jin; D R Gossett; S Wang; D Yang; Y Cao; J Chen; R Guo; R K Reynolds; J Lin
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.